Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Pancreatic cancer has the highest mortality rate due to lack of early detection biomarkers.
• Key gene mutations (KRAS, CDKN2A, TP53, SMAD4) drive pancreatic cancer, with KRAS mutations in over 80% of cases.
• The pancreas's metabolic and hormonal functions are critical, and malignancy leads to severe health consequences.

Purpose of the Study:

• To review the effectiveness and molecular mechanisms of small molecule inhibitors for pancreatic cancer.
• To discuss both natural and synthetic inhibitors, including those in clinical trials and commercial drugs.
• To explore the potential of single and combined therapies in treating pancreatic cancer.

Main Methods:

• Literature review of small molecule inhibitors targeting pancreatic cancer.
• Analysis of molecular mechanisms of action for various inhibitors.
• Discussion of clinical trial data and commercial drug applications.

Main Results:

• Small molecule inhibitors show promise in targeting KRAS and other key pathways in pancreatic cancer.
• Both natural and synthetic compounds exhibit anti-pancreatic cancer activity.
• Combined therapies may offer enhanced benefits over single-agent treatments.

Conclusions:

• There is a critical need for effective pancreatic cancer treatments, particularly targeting KRAS mutations.
• Small molecule inhibitors represent a promising therapeutic strategy for pancreatic cancer.
• Further research into novel inhibitors and combination therapies is essential for improving patient outcomes.